# Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

> **NCT03722407** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 29 (actual)

## Conditions studied

- Chronic Myelomonocytic Leukemia
- Leukemia

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT03722407
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-28
- **Primary completion:** 2022-09-19
- **Final completion:** 2026-06-01
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03722407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03722407, "Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03722407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*